Heavy Q4 awaiting
Tenaya plans to report additional interim data from the MyPEAK-1 clinical trial in the fourth quarter of 2026.
Tenaya is pursuing alignment with regulatory authorities on late-stage pivotal trial plans for TN-201. The company plans to provide an update on the status of these discussions in the fourth quarter of 2026
Tenaya expects to report additional interim data from the RIDGE-1 clinical trial in the fourth quarter of 2026.
Tenaya is currently engaging with regulators on late-stage pivotal trial planning for TN-401 and plans to provide an update on the status of its discussions in the fourth quarter of 2026.
The company intends to share additional details regarding its TN-301 development plans in the fourth quarter of 2026,
If at least 75% of those are positive, stock can jump up to hopefully no less than $1-$1.2